132 related articles for article (PubMed ID: 38047057)
1. Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario.
Shrivastva S; Bala SC; Chennamaneni R; Konatam ML; Pydi VR; Prasad KS; Gundeti S
South Asian J Cancer; 2023 Jul; 12(3):233-237. PubMed ID: 38047057
[TBL] [Abstract][Full Text] [Related]
2. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
3. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
4. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
5. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
Cao L; Cai G; Chang C; Miao AY; Yu XL; Yang ZZ; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
Oncologist; 2015 Jun; 20(6):605-14. PubMed ID: 25933931
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.
Bachir B; Anouti S; Abi Jaoude J; Kayali M; Tfayli A; de Azambuja E; Poortmans P; Zeidan YH
Int J Radiat Oncol Biol Phys; 2022 May; 113(1):135-142. PubMed ID: 34986381
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction.
Nowsheen S; Aziz K; Park JY; Lerman A; Villarraga HR; Ruddy KJ; Herrmann J
J Am Heart Assoc; 2018 Aug; 7(15):e008637. PubMed ID: 30371238
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity with adjuvant trastuzumab use in breast cancer: A single institution's experience.
Aldiab A
J Saudi Heart Assoc; 2010 Jul; 22(3):133-6. PubMed ID: 23960606
[TBL] [Abstract][Full Text] [Related]
13. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data.
Kim EK; Cho J; Kim JY; Chang SA; Park SJ; Choi JO; Lee SC; Ahn JS; Park SW; Im YH; Jeon ES; Park YH
Cancer Res Treat; 2019 Apr; 51(2):727-736. PubMed ID: 30177584
[TBL] [Abstract][Full Text] [Related]
14. Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience.
da Fonseca LG; de Melo Gagliato D; Takahashi TK; Mak MP; Barroso-Sousa R; Testa L; Helena VP; de Paula Costa R; Hoff PM; Mano MS
Breast Care (Basel); 2014 Apr; 9(4):255-60. PubMed ID: 25404884
[TBL] [Abstract][Full Text] [Related]
15. Cardiac toxicity of patients on short course trastuzumab in combination with chemotherapy (FinHer Protocol) in breast cancer.
T M A; Joseph P R; Abraham AA; Mathew M; Kumar BS
Breast J; 2021 Nov; 27(11):811-816. PubMed ID: 34510637
[TBL] [Abstract][Full Text] [Related]
16. Acute Cardiotoxicity With Concurrent Trastuzumab and Hypofractionated Radiation Therapy in Breast Cancer Patients.
Sayan M; Abou Yehia Z; Gupta A; Toppmeyer D; Ohri N; Haffty BG
Front Oncol; 2019; 9():970. PubMed ID: 31632906
[No Abstract] [Full Text] [Related]
17. Is there a window of opportunity to optimize trastuzumab cardiac monitoring?
Rala de Paula BH; Costa METF; de Sousa CAM; Bines J
World J Cardiol; 2022 Jul; 14(7):403-410. PubMed ID: 36161060
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
19. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration.
Sendur MA; Aksoy S; Ozdemir NY; Yazici O; Zengin N; Altundag K
Curr Med Res Opin; 2014 Dec; 30(12):2535-42. PubMed ID: 25222762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
